metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus irinotecan, paclitaxel
	avelumab alone
	JAVELIN Gastric 300, 2018 Ann. Oncol. 2018; 29:2052-2060 NCT02625623	RCT	mGC or mGEJC - L2 - all population	avelumab	physician's choice of chemotherapy (paclitaxel or irinotecan)	patients with unresectable, recurrent, locally advanced, or metastatic gastric cancer/gastro-oesophageal junction cancer with disease progression after second-line treatment	185 / 186	some concern	inconclusive	inconclusive 10 % increase in deaths (OS) (PE) statistically significant 73 % increase in progression or deaths (PFS) statistically significant 63 % decrease in DCR
mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative
versus Standard of Care (SoC)
	avelumab alone
	JAVELIN Gastric 100, 2020 Future Oncol 2019; 15:567-577 NCT02625610	RCT	mGC or mGEJC - M - HER2 negative	avelumab maintenance	chemotherapy	patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer. all patients received first-line chemotherapy	249 / 250	some concern	inconclusive	inconclusive 9 % decrease in deaths (OS) (PE) statistically significant 38 % decrease in DCR
mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
	avelumab alone
	JAVELIN Gastric 100 (PDL1>1%), 2020 Future Oncol 2019; 15:567-577 NCT02625610	RCT	mGC or mGEJC - M - HER2 neg/PDL1 positive	avelumab maintenance	chemotherapy	patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer. all patients received first-line chemotherapy	30 / 24	some concern	inconclusive	inconclusive 13 % increase in deaths (OS) (PE)